Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2015-11-06 Earnings Release
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 6, 2015, by Insmed Incorporated. It specifically mentions Item 2.02 - Results of Operations and Financial Condition, and includes a press release regarding financial results for the three and nine months ended September 30, 2015. The document is relatively short (3150 characters) and primarily furnishes a press release as an exhibit. The language indicates this is a current report announcing financial results, which aligns with an Earnings Release (ER). It is not a full quarterly or annual report, nor is it a certification or announcement of a report publication. Therefore, the best classification is Earnings Release (ER).
2015-11-06 English
10-Q
Interim / Quarterly Report Q3 2015
2015-11-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 15, 2015. It reports the entry into a material definitive agreement between the company and another party. The content focuses on the description of a commercial fill/finish services agreement, including terms, payment, and termination clauses. There is no financial statement or detailed financial performance data. The document is relatively short (4304 characters) and is a current report on a material event rather than a full financial report or earnings release. This type of filing is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a material contract and does not fit into more specific categories like Annual Report, Earnings Release, or Capital Update.
2015-09-18 English
PRIMARY DOCUMENT
Director's Dealing
2015-09-03 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 6, 2015, by Insmed Incorporated. It specifically references Item 2.02 - Results of Operations and Financial Condition, and mentions a press release regarding financial results for the three and six months ended June 30, 2015. The document states that the press release is furnished as an exhibit and is not deemed filed for certain regulatory purposes. The length of the document is 3107 characters, which is relatively short and primarily serves as an announcement of financial results rather than containing detailed financial statements or analysis. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the appropriate classification is Earnings Release (ER).
2015-08-06 English
10-Q
Interim / Quarterly Report Q2 2015
2015-08-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.